Faricimab is a novel, investigational bispecific antibody that targets both angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF), two key drivers of angiogenesis (the growth of new blood vessels) and vascular permeability (leakage of fluid into the retina). By blocking both Ang-2 and VEGF, faricimab is thought to reduce the underlying pathology of ocular diseases such as age-related macular degeneration (AMD) and diabetic macular edema (DME).

свернуть